Amgen
Information

Amgen

ISIN
US0311621009
Ticker
AMGN
ISIN
US0311621009
Ticker
AMGN
New Post

Information

large cap stock
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
Employees
24,300
Industries
Biotechnology & Drugs
Sector
Health Care

Community

Financials

52W Low
$198.64
52W High
$276.69
Market Capitalization
$128.93B
EBITDA
$10.76B
Beta
0.60653

Analyst Ratings

Target Price
$240.46
This security is covered by 28 analysts
Buy
11
Hold
15
Sell
2

Dividends

Activities

Trending